Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc.) on November 9, 2020. The filing reports the appointment of a new Chief Financial and Operating Officer effective November 2, 2020.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and personnel changes.
- New Executive Compensation: Steve Mahoney's annual base salary for fiscal year 2020 is set at $420,000 (prorated based on start date).
- Incentive Compensation: Target amount is 40% of the base salary.
Material Changes
The primary material change is the appointment of Steve Mahoney as Chief Financial and Operating Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer. Consequently, Cindy Driscoll, who served as Vice President, Finance, ceased her interim duties as Principal Financial and Accounting Officer on November 5, 2020, though she remains Vice President, Finance.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that Mr. Mahoney brings over 20 years of biotechnology experience, including roles at Kiniksa Pharmaceuticals and Synageva Biopharma. No unusual items or special contingencies are reported.
Investor Verification Checklist
- Verify the company name is Magenta Therapeutics, Inc. (Ticker: MGTA), not Dianthus Therapeutics.
- Confirm the effective date of the new CFO appointment (November 2, 2020) versus the filing date (November 9, 2020).
- Review the employment agreement terms regarding the $420,000 base salary and 40% target incentive.
- Check the transition of financial officer responsibilities from Cindy Driscoll to Steve Mahoney.